Of note, we found high titres of anti-MICL antibodies in patients with SLE (Fig. 3g) and severe COVID-19 (Fig. 3h), both of which are inflammatory disorders where disease severity has been linked to NETosis15,47. Here, CLEC12A is linked to systemic lupus erythematosus.